 Peter Mourani
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 382 | 4.620 |
Why?
| | Heart Arrest | 22 | 2025 | 339 | 3.430 |
Why?
| | Intensive Care Units, Pediatric | 34 | 2025 | 233 | 3.400 |
Why?
| | Cardiopulmonary Resuscitation | 22 | 2025 | 250 | 3.340 |
Why?
| | Respiration, Artificial | 20 | 2024 | 643 | 2.800 |
Why?
| | Pneumonia, Ventilator-Associated | 4 | 2025 | 53 | 2.030 |
Why?
| | Critical Illness | 25 | 2025 | 809 | 1.910 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1903 | 1.860 |
Why?
| | Infant, Premature | 17 | 2021 | 568 | 1.840 |
Why?
| | Microbiota | 9 | 2024 | 763 | 1.800 |
Why?
| | Shock, Septic | 12 | 2024 | 221 | 1.700 |
Why?
| | Prospective Studies | 54 | 2025 | 7598 | 1.610 |
Why?
| | Respiratory Tract Infections | 7 | 2024 | 395 | 1.510 |
Why?
| | Sepsis | 13 | 2025 | 611 | 1.510 |
Why?
| | Child | 103 | 2025 | 22037 | 1.470 |
Why?
| | Respiratory Insufficiency | 6 | 2024 | 316 | 1.460 |
Why?
| | Infant, Newborn | 46 | 2025 | 6059 | 1.380 |
Why?
| | Trachea | 3 | 2017 | 236 | 1.290 |
Why?
| | Infant | 58 | 2025 | 9467 | 1.190 |
Why?
| | Child, Preschool | 52 | 2025 | 11097 | 1.160 |
Why?
| | Skin Pigmentation | 2 | 2025 | 49 | 1.140 |
Why?
| | Oximetry | 2 | 2025 | 96 | 1.110 |
Why?
| | Vascular Diseases | 5 | 2020 | 244 | 1.070 |
Why?
| | Premature Birth | 4 | 2021 | 331 | 0.950 |
Why?
| | Critical Care | 6 | 2021 | 584 | 0.930 |
Why?
| | Humans | 147 | 2025 | 137514 | 0.930 |
Why?
| | Lung | 10 | 2024 | 4066 | 0.920 |
Why?
| | Intubation, Intratracheal | 4 | 2024 | 259 | 0.900 |
Why?
| | Epinephrine | 5 | 2025 | 145 | 0.870 |
Why?
| | Accelerometry | 1 | 2024 | 97 | 0.860 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 236 | 0.850 |
Why?
| | Echocardiography | 7 | 2021 | 659 | 0.850 |
Why?
| | Heart Ventricles | 2 | 2021 | 792 | 0.820 |
Why?
| | Intensive Care Units | 11 | 2025 | 803 | 0.810 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 51 | 0.810 |
Why?
| | Influenza, Human | 9 | 2023 | 632 | 0.800 |
Why?
| | Male | 76 | 2025 | 67718 | 0.750 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 544 | 0.750 |
Why?
| | Quality of Life | 13 | 2024 | 2870 | 0.730 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 283 | 0.720 |
Why?
| | Female | 79 | 2025 | 73162 | 0.720 |
Why?
| | Gestational Age | 8 | 2025 | 903 | 0.710 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 128 | 0.710 |
Why?
| | Patient Discharge | 13 | 2024 | 895 | 0.680 |
Why?
| | Bacteria | 6 | 2025 | 858 | 0.680 |
Why?
| | Adolescent | 48 | 2025 | 21555 | 0.680 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 284 | 0.640 |
Why?
| | Aftercare | 5 | 2024 | 210 | 0.600 |
Why?
| | Nutritional Support | 1 | 2017 | 34 | 0.560 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 109 | 0.550 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 187 | 0.540 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 107 | 0.540 |
Why?
| | Patient Readmission | 3 | 2024 | 696 | 0.530 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 52 | 0.510 |
Why?
| | Metagenomics | 6 | 2025 | 167 | 0.500 |
Why?
| | Coinfection | 3 | 2022 | 137 | 0.490 |
Why?
| | Risk Factors | 21 | 2024 | 10356 | 0.490 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.480 |
Why?
| | Pulmonary Artery | 4 | 2024 | 1083 | 0.480 |
Why?
| | Energy Intake | 1 | 2017 | 478 | 0.460 |
Why?
| | Nitric Oxide | 6 | 2022 | 914 | 0.450 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 20 | 0.440 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 13 | 0.430 |
Why?
| | Chlorides | 3 | 2020 | 140 | 0.430 |
Why?
| | Metapneumovirus | 1 | 2013 | 16 | 0.430 |
Why?
| | Retrospective Studies | 28 | 2025 | 15628 | 0.420 |
Why?
| | Myocardial Contraction | 1 | 2015 | 343 | 0.420 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 101 | 0.420 |
Why?
| | Pneumonia, Bacterial | 2 | 2025 | 117 | 0.420 |
Why?
| | Oxygen | 4 | 2024 | 943 | 0.410 |
Why?
| | Proteomics | 5 | 2024 | 1113 | 0.410 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 160 | 0.410 |
Why?
| | Exercise | 1 | 2024 | 2024 | 0.410 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 103 | 0.390 |
Why?
| | Lung Diseases | 2 | 2010 | 768 | 0.380 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 358 | 0.380 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 222 | 0.380 |
Why?
| | Bacterial Infections | 3 | 2023 | 251 | 0.380 |
Why?
| | Energy Metabolism | 1 | 2017 | 895 | 0.370 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.370 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 540 | 0.370 |
Why?
| | Biomarkers | 11 | 2025 | 4172 | 0.370 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.360 |
Why?
| | Drug Resistance, Bacterial | 2 | 2025 | 183 | 0.360 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 389 | 0.350 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 313 | 0.350 |
Why?
| | Bereavement | 2 | 2021 | 54 | 0.350 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 538 | 0.340 |
Why?
| | Influenza A virus | 3 | 2020 | 109 | 0.340 |
Why?
| | Cardiopulmonary Bypass | 2 | 2025 | 209 | 0.330 |
Why?
| | Wilms Tumor | 1 | 2011 | 86 | 0.330 |
Why?
| | Milrinone | 2 | 2021 | 29 | 0.330 |
Why?
| | Vasodilator Agents | 3 | 2021 | 333 | 0.330 |
Why?
| | Health Resources | 5 | 2024 | 122 | 0.330 |
Why?
| | Proteome | 2 | 2024 | 474 | 0.320 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1580 | 0.320 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 811 | 0.320 |
Why?
| | Logistic Models | 7 | 2024 | 2064 | 0.310 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 44 | 0.300 |
Why?
| | Coronary Care Units | 2 | 2018 | 19 | 0.300 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 89 | 0.290 |
Why?
| | Hemodynamics | 4 | 2025 | 1114 | 0.290 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 66 | 0.290 |
Why?
| | Sulfones | 1 | 2008 | 110 | 0.290 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 127 | 0.280 |
Why?
| | Caregivers | 4 | 2024 | 872 | 0.280 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 236 | 0.280 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 65 | 0.280 |
Why?
| | Heparitin Sulfate | 2 | 2024 | 50 | 0.280 |
Why?
| | Heart Diseases | 2 | 2023 | 359 | 0.270 |
Why?
| | Administration, Inhalation | 5 | 2022 | 683 | 0.270 |
Why?
| | Time Factors | 11 | 2025 | 6817 | 0.270 |
Why?
| | Staphylococcus | 2 | 2017 | 76 | 0.270 |
Why?
| | Cohort Studies | 13 | 2022 | 5730 | 0.260 |
Why?
| | Length of Stay | 5 | 2025 | 1210 | 0.260 |
Why?
| | Quality Improvement | 3 | 2022 | 1161 | 0.260 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 400 | 0.260 |
Why?
| | Research Design | 4 | 2022 | 1116 | 0.260 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 292 | 0.250 |
Why?
| | Piperazines | 1 | 2008 | 351 | 0.250 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 402 | 0.250 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 1800 | 0.250 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 201 | 0.250 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5139 | 0.240 |
Why?
| | Hospital Mortality | 8 | 2023 | 902 | 0.240 |
Why?
| | Cloud Computing | 1 | 2025 | 7 | 0.240 |
Why?
| | Spectrophotometry | 1 | 2025 | 61 | 0.240 |
Why?
| | Pregnancy | 10 | 2024 | 6745 | 0.230 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 71 | 0.230 |
Why?
| | Heart Bypass, Right | 1 | 2024 | 17 | 0.220 |
Why?
| | Diastole | 3 | 2019 | 150 | 0.220 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2025 | 54 | 0.220 |
Why?
| | Arteriovenous Malformations | 1 | 2024 | 27 | 0.220 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 15 | 0.220 |
Why?
| | Hypercapnia | 1 | 2024 | 53 | 0.220 |
Why?
| | Arteriovenous Fistula | 1 | 2024 | 36 | 0.220 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 9 | 0.220 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 35 | 0.220 |
Why?
| | Bradycardia | 1 | 2024 | 55 | 0.220 |
Why?
| | Pregnancy in Diabetics | 2 | 2024 | 123 | 0.210 |
Why?
| | Tunica Intima | 1 | 2004 | 84 | 0.210 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 446 | 0.210 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2024 | 130 | 0.210 |
Why?
| | Viruses | 1 | 2024 | 112 | 0.210 |
Why?
| | Pulmonary Veins | 1 | 2024 | 99 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2025 | 10821 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3722 | 0.200 |
Why?
| | Respiration | 1 | 2024 | 198 | 0.200 |
Why?
| | Feasibility Studies | 2 | 2024 | 950 | 0.200 |
Why?
| | Employment | 1 | 2024 | 177 | 0.200 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2857 | 0.200 |
Why?
| | United States | 13 | 2025 | 14696 | 0.200 |
Why?
| | Hypoxia | 3 | 2024 | 1108 | 0.200 |
Why?
| | Wounds and Injuries | 2 | 2021 | 752 | 0.200 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 171 | 0.200 |
Why?
| | Blood Proteins | 1 | 2024 | 250 | 0.190 |
Why?
| | Cotinine | 1 | 2023 | 87 | 0.190 |
Why?
| | Hypotension | 1 | 2023 | 123 | 0.190 |
Why?
| | Age Factors | 6 | 2021 | 3301 | 0.190 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 223 | 0.190 |
Why?
| | Neuroimaging | 1 | 2025 | 291 | 0.190 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 23 | 0.190 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 11 | 0.190 |
Why?
| | Fontan Procedure | 1 | 2024 | 179 | 0.190 |
Why?
| | Virus Diseases | 1 | 2024 | 217 | 0.190 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 260 | 0.190 |
Why?
| | Protein Kinases | 1 | 2004 | 319 | 0.190 |
Why?
| | Indoles | 1 | 2025 | 415 | 0.190 |
Why?
| | Sodium | 1 | 2022 | 218 | 0.180 |
Why?
| | Central Venous Catheters | 1 | 2022 | 51 | 0.180 |
Why?
| | Smoke | 1 | 2023 | 144 | 0.180 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 182 | 0.180 |
Why?
| | Central Venous Pressure | 1 | 2021 | 14 | 0.180 |
Why?
| | Prone Position | 1 | 2021 | 30 | 0.180 |
Why?
| | Capnography | 1 | 2021 | 16 | 0.180 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 75 | 0.180 |
Why?
| | Shock | 1 | 2022 | 95 | 0.180 |
Why?
| | Thoracic Injuries | 1 | 2021 | 55 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 16 | 0.180 |
Why?
| | Iloprost | 1 | 2021 | 45 | 0.170 |
Why?
| | Spinal Injuries | 1 | 2021 | 51 | 0.170 |
Why?
| | Common Data Elements | 1 | 2020 | 14 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 142 | 0.170 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 56 | 0.170 |
Why?
| | Parents | 4 | 2021 | 1363 | 0.170 |
Why?
| | Young Adult | 10 | 2024 | 13243 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 344 | 0.170 |
Why?
| | Vasopressins | 1 | 2021 | 64 | 0.170 |
Why?
| | Multiple Trauma | 1 | 2021 | 101 | 0.170 |
Why?
| | Extremities | 1 | 2021 | 130 | 0.170 |
Why?
| | Patient Positioning | 1 | 2021 | 68 | 0.170 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 111 | 0.170 |
Why?
| | Communicable Diseases | 1 | 2022 | 160 | 0.170 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1286 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 646 | 0.170 |
Why?
| | Adult | 13 | 2024 | 37821 | 0.170 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 95 | 0.170 |
Why?
| | Epoprostenol | 1 | 2021 | 136 | 0.170 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 16 | 0.170 |
Why?
| | Abdominal Injuries | 1 | 2021 | 123 | 0.160 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 168 | 0.160 |
Why?
| | Brain Injuries | 1 | 2025 | 493 | 0.160 |
Why?
| | Morbidity | 4 | 2022 | 322 | 0.160 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1524 | 0.160 |
Why?
| | Medical Audit | 1 | 2020 | 76 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2025 | 1950 | 0.160 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 23 | 0.160 |
Why?
| | Computational Biology | 2 | 2025 | 645 | 0.160 |
Why?
| | Medical Records | 1 | 2020 | 173 | 0.150 |
Why?
| | Nervous System Diseases | 1 | 2022 | 265 | 0.150 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 430 | 0.150 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 99 | 0.150 |
Why?
| | Medicine | 1 | 2020 | 120 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 126 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 160 | 0.150 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 123 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2020 | 3292 | 0.140 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 27 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2420 | 0.140 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 82 | 0.140 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 274 | 0.140 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 37 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 531 | 0.140 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 316 | 0.140 |
Why?
| | Academic Medical Centers | 2 | 2017 | 498 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 83 | 0.140 |
Why?
| | RNA, Bacterial | 2 | 2024 | 186 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 92 | 0.140 |
Why?
| | Chorioamnionitis | 1 | 2017 | 42 | 0.140 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 68 | 0.140 |
Why?
| | Inservice Training | 1 | 2018 | 113 | 0.140 |
Why?
| | Blood Pressure | 4 | 2023 | 1776 | 0.140 |
Why?
| | Respiratory System | 1 | 2018 | 158 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 696 | 0.130 |
Why?
| | Mutation, Missense | 1 | 2019 | 338 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 180 | 0.130 |
Why?
| | Hospitalization | 4 | 2023 | 2197 | 0.130 |
Why?
| | Delirium | 1 | 2018 | 85 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 571 | 0.130 |
Why?
| | Ultrasonography | 2 | 2025 | 750 | 0.130 |
Why?
| | Chronic Disease | 3 | 2022 | 1790 | 0.130 |
Why?
| | Heart Failure | 2 | 2021 | 2222 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 595 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 106 | 0.130 |
Why?
| | Incidence | 3 | 2024 | 2792 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2024 | 784 | 0.130 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 141 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 347 | 0.130 |
Why?
| | Pneumonia | 1 | 2022 | 638 | 0.130 |
Why?
| | Prognosis | 5 | 2025 | 4031 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1312 | 0.120 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 16 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 704 | 0.120 |
Why?
| | Heart Defects, Congenital | 2 | 2024 | 832 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 533 | 0.120 |
Why?
| | Survival Rate | 4 | 2024 | 1980 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 252 | 0.120 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 47 | 0.120 |
Why?
| | Needs Assessment | 1 | 2017 | 368 | 0.120 |
Why?
| | Fibroblasts | 1 | 2020 | 990 | 0.120 |
Why?
| | Hyperglycemia | 1 | 2019 | 346 | 0.120 |
Why?
| | Mothers | 2 | 2022 | 752 | 0.120 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 191 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2838 | 0.120 |
Why?
| | Indiana | 1 | 2015 | 33 | 0.120 |
Why?
| | Medical Informatics | 1 | 2016 | 100 | 0.110 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.110 |
Why?
| | Delphi Technique | 3 | 2020 | 273 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 368 | 0.110 |
Why?
| | Trauma Centers | 3 | 2022 | 422 | 0.110 |
Why?
| | Vasoconstrictor Agents | 2 | 2025 | 138 | 0.110 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 12 | 0.110 |
Why?
| | Aged | 5 | 2024 | 23798 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2681 | 0.110 |
Why?
| | Schools, Medical | 1 | 2015 | 146 | 0.110 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 533 | 0.110 |
Why?
| | Birth Weight | 1 | 2017 | 516 | 0.100 |
Why?
| | Hyperoxia | 2 | 2024 | 90 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 424 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 679 | 0.100 |
Why?
| | Transcriptome | 3 | 2024 | 974 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 854 | 0.100 |
Why?
| | Signal Transduction | 2 | 2020 | 5096 | 0.100 |
Why?
| | Smoking | 2 | 2018 | 1639 | 0.100 |
Why?
| | Hypertension | 2 | 2019 | 1293 | 0.100 |
Why?
| | Patient Care Team | 1 | 2018 | 629 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 49 | 0.100 |
Why?
| | Viral Load | 2 | 2024 | 462 | 0.100 |
Why?
| | Risk Assessment | 5 | 2018 | 3439 | 0.100 |
Why?
| | Nasopharynx | 2 | 2023 | 75 | 0.100 |
Why?
| | Colorado | 4 | 2017 | 4521 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 84 | 0.100 |
Why?
| | Adaptive Immunity | 2 | 2024 | 164 | 0.100 |
Why?
| | Physicians | 1 | 2021 | 904 | 0.100 |
Why?
| | Risk | 2 | 2012 | 905 | 0.100 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 202 | 0.090 |
Why?
| | Polysaccharides | 1 | 2012 | 87 | 0.090 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 22 | 0.090 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 38 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 426 | 0.090 |
Why?
| | Enoxaparin | 1 | 2012 | 62 | 0.090 |
Why?
| | Suction | 1 | 2011 | 34 | 0.090 |
Why?
| | Bacterial Load | 1 | 2011 | 68 | 0.090 |
Why?
| | Carbon Dioxide | 2 | 2023 | 267 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 305 | 0.090 |
Why?
| | Immunomodulation | 1 | 2012 | 98 | 0.090 |
Why?
| | Grief | 2 | 2021 | 38 | 0.090 |
Why?
| | Pressure | 2 | 2023 | 244 | 0.090 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 164 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 608 | 0.090 |
Why?
| | Metagenome | 1 | 2011 | 147 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2017 | 1167 | 0.090 |
Why?
| | Anticoagulants | 2 | 2012 | 665 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 256 | 0.090 |
Why?
| | Interferons | 2 | 2022 | 199 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 275 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1285 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 393 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 40 | 0.080 |
Why?
| | Fetal Blood | 1 | 2012 | 327 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2024 | 555 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2020 | 77 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 493 | 0.080 |
Why?
| | Influenza Vaccines | 1 | 2014 | 551 | 0.080 |
Why?
| | Potassium | 2 | 2022 | 151 | 0.080 |
Why?
| | Blood Glucose | 2 | 2019 | 2183 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 58 | 0.070 |
Why?
| | Survivors | 2 | 2022 | 489 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 69 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 106 | 0.070 |
Why?
| | Stem Cells | 1 | 2012 | 589 | 0.070 |
Why?
| | Purines | 1 | 2008 | 176 | 0.070 |
Why?
| | Pediatrics | 1 | 2016 | 1123 | 0.070 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5772 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 974 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1242 | 0.070 |
Why?
| | Stroke Volume | 2 | 2021 | 619 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 175 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1320 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2018 | 2641 | 0.070 |
Why?
| | Gene Expression | 2 | 2022 | 1505 | 0.060 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 177 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Clinical Competence | 2 | 2023 | 1093 | 0.060 |
Why?
| | Phenotype | 2 | 2023 | 3205 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 47 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 52 | 0.060 |
Why?
| | Angiopoietin-2 | 1 | 2024 | 16 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 100 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 795 | 0.060 |
Why?
| | Hypocapnia | 1 | 2024 | 8 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 528 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 48 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 152 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 44 | 0.050 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 8 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1129 | 0.050 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 41 | 0.050 |
Why?
| | Cytokines | 1 | 2012 | 2095 | 0.050 |
Why?
| | Aorta | 2 | 2004 | 421 | 0.050 |
Why?
| | Disaccharides | 1 | 2023 | 19 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 71 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 107 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 22 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 111 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2023 | 38 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2023 | 70 | 0.050 |
Why?
| | Glycocalyx | 1 | 2023 | 28 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 35 | 0.050 |
Why?
| | Probability | 1 | 2004 | 311 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 34 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 126 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 179 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 107 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 372 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 56 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 152 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 162 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 2193 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 253 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 596 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 45 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 275 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 653 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2024 | 654 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 366 | 0.050 |
Why?
| | White Matter | 1 | 2023 | 148 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 437 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 64 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 304 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 212 | 0.040 |
Why?
| | Neonatologists | 1 | 2021 | 7 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 471 | 0.040 |
Why?
| | Influenza in Birds | 1 | 2020 | 3 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2501 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 451 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 414 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 87 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 74 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 845 | 0.040 |
Why?
| | Stromal Cells | 1 | 2020 | 111 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2113 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 46 | 0.040 |
Why?
| | Birds | 1 | 2020 | 91 | 0.040 |
Why?
| | Software | 1 | 2025 | 670 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 18 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 77 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 336 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 37 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 525 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1060 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1762 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 49 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 301 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 84 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 790 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 164 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 157 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 117 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 198 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 832 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 188 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 678 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1029 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 306 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 452 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 412 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 266 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 309 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3546 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 277 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 407 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 546 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 172 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 920 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 309 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5676 | 0.030 |
Why?
| | Data Collection | 1 | 2020 | 674 | 0.030 |
Why?
| | Middle Aged | 3 | 2024 | 33355 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 809 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 685 | 0.030 |
Why?
| | Creatinine | 1 | 2019 | 501 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 357 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2017 | 75 | 0.030 |
Why?
| | Animals | 5 | 2020 | 37011 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 651 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1703 | 0.030 |
Why?
| | Causality | 1 | 2017 | 127 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 203 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 308 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1770 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1486 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1233 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2020 | 528 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 4206 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 163 | 0.030 |
Why?
| | Family | 1 | 2020 | 667 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 277 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 403 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2021 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 851 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 129 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 599 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 653 | 0.030 |
Why?
| | Communication | 1 | 2021 | 874 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1618 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2838 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 973 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 1012 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 740 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 42 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1619 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 185 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2039 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 2229 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2054 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2837 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1351 | 0.020 |
Why?
| | Immune System | 1 | 2013 | 177 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1465 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1408 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1702 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 183 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1775 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 339 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 632 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 558 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 563 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1185 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2755 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 780 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 386 | 0.010 |
Why?
| | Mice | 1 | 2020 | 17843 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 232 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 536 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3708 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|